Literature DB >> 1787913

The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.

H Tohgi1, T Abe, T Kikuchi, S Takahashi, Y Nozaki.   

Abstract

We determined concentrations of 3-O-methyldopa (3-OMD), L-3,4-dihydroxyphenylalanine (L-dopa), dopamine (DA) and other related substances in the cerebrospinal fluid in patients with Parkinson's disease (PD) 15 h after L-dopa/carbidopa medication, and compared patients with and without the wearing-off phenomenon. Concentrations of 3-OMD significantly increased, and the ratio of DA to 3-OMD was significantly shifted in favor of 3-OMD in patients with the wearing-off compared with patients without the wearing-off. However, concentrations of L-dopa, DA, and homovanillic acid (HVA) were not different between the groups. These results suggest that even if 3-OMD is related to the pathogenesis of the wearing-off, it is not through competition with L-dopa for uptake into the brain, but through other unknown mechanisms within the brain.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1787913     DOI: 10.1016/0304-3940(91)90422-p

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

Review 1.  Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

Authors:  S Kaakkola
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

2.  Microdialysis with radiometric monitoring of L-[β-11C]DOPA to assess dopaminergic metabolism: effect of inhibitors of L-amino acid decarboxylase, monoamine oxidase, and catechol-O-methyltransferase on rat striatal dialysate.

Authors:  Maki Okada; Ryuji Nakao; Rie Hosoi; Ming-Rong Zhang; Toshimitsu Fukumura; Kazutoshi Suzuki; Osamu Inoue
Journal:  J Cereb Blood Flow Metab       Date:  2010-04-21       Impact factor: 6.200

Review 3.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  The role of 3-O-methyldopa in the side effects of L-dopa.

Authors:  Eun-Sook Y Lee; Hongtao Chen; Jennifer King; Clivel Charlton
Journal:  Neurochem Res       Date:  2007-08-24       Impact factor: 3.996

5.  Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.

Authors:  Ki Sung Kang; Noriko Yamabe; Yujing Wen; Masayuki Fukui; Bao Ting Zhu
Journal:  Brain Res       Date:  2012-12-01       Impact factor: 3.252

6.  Effects of 3-O-methyl on L-dopa-facilitated synthesis and efflux of dopamine from rat striatal slices.

Authors:  W Y Chang; R A Webster
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

7.  Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis.

Authors:  Richard P Allen; James R Connor; Keith Hyland; Christopher J Earley
Journal:  Sleep Med       Date:  2008-01-28       Impact factor: 3.492

8.  The mechanism of perturbation in monoamine metabolism by L-dopa therapy: in vivo and in vitro studies.

Authors:  W Maruyama; M Naoi; A Takahashi; H Watanabe; Y Konagaya; K Mokuno; S Hasegawa; D Nakahara
Journal:  J Neural Transm Gen Sect       Date:  1992

9.  Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone.

Authors:  Joe Yamamoto; Tomohiro Omura; Sachiko Kasamo; Shota Yamamoto; Masayoshi Kawata; Atsushi Yonezawa; Yosuke Taruno; Hisako Endo; Hitoshi Aizawa; Nobukatsu Sawamoto; Kazuo Matsubara; Ryosuke Takahashi; Yoshikazu Tasaki
Journal:  J Neural Transm (Vienna)       Date:  2020-11-02       Impact factor: 3.575

10.  Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies.

Authors:  Ki Sung Kang; Yujing Wen; Noriko Yamabe; Masayuki Fukui; Stephanie C Bishop; Bao Ting Zhu
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.